Week in Review: Qiming Launches $500 Million Fund for Listed Healthcare Companies

Deals and Financings   Qiming, a China-based VC firm, raised more than $500 million for a fund that will invest in shares of listed healthcare companies with a focus on Greater China and Asia; ProfoundBio, a Seattle-Suzhou ADC company, announced a deal worth up to $246 million for rights to use Synaffix's novel linker-payload technologies; Shanghai Junshi Bio formed a mRNA JV with Hangzhou 's Immorna to develop new drugs for cancer, infectious and rare diseases; Eluminex Biosciences ( Suzhou ), an ophthalmology biotech, agreed to pay up to $108 million for global rights to a biosynthetic cornea from FibroGen; Juventas Cell Therapy of Beijing closed a $62 million Series C round to develop its lead CAR-T candidate, stem cell technology and gene editing platform; Beijing Mabworks Biotech filed an IPO application to develop mAbs and multi-specific antibodies for oncology and autoimmune diseases; Shanghai 's GenFleet Therapeutics partnered with Insilico Medicine, a Hong Kong AI-based drug discovery company, to identify new "game-changer" drugs;   Company News   ImmVira, a Shenzhen oncolytic virus company, opened its pilot-scale production line to manufacture next-gen oncolytic viruses;  Trials and Approvals   Nanjing Frontier Biotech announced positive top-line results from a China Phase III trial of its long-acting two-drug therapy for AIDS; Ascletis Pharma of  Hangzhou  was approved to start its Phase III trial of ASC40 combined with bevacizumab for patients with recurrent glioblastoma; Jilin Qilu Pharma enrolled the first patient in a  China  bridging trial of Vicineum in patients with non-muscle invasive bladder cancer; Shanghai 's Antengene was approved to start an Australian Phase I trial of its PD-L1/4-1BB bispecific in patients with advanced solid tumors.  Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: FGEN) (HK: 1672) (HK: 6996) Share this with colleagues: // //